子宫肌瘤保守治疗的研究进展
Research Progress in Conservative Treatment of Uterine Myoma
DOI: 10.12677/ACM.2024.142357, PDF,   
作者: 刘琦琦, 刘思杨：黑龙江中医药大学研究生院，黑龙江 哈尔滨；杨新鸣*：黑龙江中医药大学附属第一医院妇科一科，黑龙江 哈尔滨
关键词: 子宫肌瘤；保守治疗；综述；Uterine Myoma； Conservative Treatment； Overview
摘要: 子宫肌瘤是育龄期女性常见的肿瘤之一，临床上多以月经量增多和经期延长为主要表现。其病因尚不明确，多与雌孕激素有关，治疗上主要是手术治疗和保守治疗两种方法，保守治疗以减少月经量、缩短经期为原则。本文就子宫肌瘤保守治疗各方案进行论述，以期为临床医生用药方案提供参考。
Abstract: Uterine myoma is one of the common tumors in women of childbearing age, with increased men-strual flow and prolonged menstrual periods as the main clinical manifestations. The etiology is not yet clear and is mostly related to estrogen and progesterone. The main treatment methods are sur-gical treatment and conservative treatment. Conservative treatment is based on reducing menstru-al flow and shortening menstrual periods. This article discusses various conservative treatment plans for uterine fibroids, in order to provide reference for clinical doctors in their medication plans.
文章引用：刘琦琦, 刘思杨, 杨新鸣. 子宫肌瘤保守治疗的研究进展[J]. 临床医学进展, 2024, 14(2): 2535-2541. https://doi.org/10.12677/ACM.2024.142357

参考文献

[1] Wise, L., Palmer, J., Stewart, E., et al. (2005) Age-Specific Incidence Rates for Self-Reported Uterine Leiomyomata in the Black Women’s Health Study. Obstetrics and Gynecology, 105, 563-568. [Google Scholar] [CrossRef] 
[2] Murji, A., Whitaker, L., Chow, T., et al. (2017) Selec-tive Progesterone Receptor Modulators (SPRMs) for Uterine Fibroids. The Cochrane Database of Systematic Reviews, 4, CD010770. [Google Scholar] [CrossRef] 
[3] Mcwilliams, M. and Chennathukuzhi, V. (2017) Recent Advances in Uterine Fibroid Etiology. Seminars in Reproductive Medicine, 35, 181-189. [Google Scholar] [CrossRef] [PubMed]
[4] Edwards, T., Giri, A., Hellwege, J., et al. (2019) A Trans-Ethnic Genome-Wide Association Study of Uterine Fibroids. Frontiers in Genetics, 10, Article No. 511. [Google Scholar] [CrossRef] [PubMed]
[5] Stewart, E., Cookson, C., Gandolfo, R., et al. (2017) Epidemiology of Uterine Fibroids: A Systematic Review. BJOG: An International Journal of Obstetrics and Gynaecology, 124, 1501-1512. [Google Scholar] [CrossRef] [PubMed]
[6] 郝子兰, 马惠荣, 林雄坡, 等. 女性子宫肌瘤发病危险因素的Meta分析[J]. 中国性科学, 2023, 32(2): 64-68.
[7] Lee, S. and Stewart, E.A. (2023) New Treatment Op-tions for Nonsurgical Management of Uterine Fibroids. Current Opinion in Obstetrics & Gynecology, 35, 288-293. [Google Scholar] [CrossRef] 
[8] Marie Madeleine, D., Luciana, C. and Jacques, D. (2021) Conservative Management of Uterine Fibroid-Related Heavy Menstrual Bleeding and Infertility: Time for a Deeper Mechanistic Understanding and an Individualized Approach. Journal of Clinical Medicine, 10, 4389-4389. [Google Scholar] [CrossRef] [PubMed]
[9] 杨丹. 子宫肌瘤是如何形成的?是否都需要行手术治疗? [J]. 科技视界, 2022(36): 42-43.
[10] 甄珠, 张刘, 丹华, 等. 子宫肌瘤的发病机制和治疗[J]. 中国药物与临床, 2022, 22(7): 665-669.
[11] 张燕, 卢翠云, 原振宇. 子宫肌瘤药物治疗的研究进展[J]. 中国城乡企业卫生, 2022, 37(4): 77-79.
[12] 王丽燕, 王兴红. 非手术治疗子宫肌瘤的研究进展[J]. 中外医学研究, 2021, 19(5): 182-185.
[13] 李萍. 子宫肌瘤药物治疗的研究进展[J]. 中国城乡企业卫生, 2022, 37(5): 16-18.
[14] 樊梦麟, 樊庆泊, 邢菲菲. 子宫肌瘤治疗方法研究进展及选择[J]. 中国现代医药杂志, 2020, 22(7): 106-108.
[15] Zhu, H.X., Lai, X.L., Wu, J.H., et al. (2022) Meta-Study of the Clinical Effect of Conservative Treatment in Uterine Fibroids. Journal of Oncology, 2022, Article ID: 6114287. [Google Scholar] [CrossRef] [PubMed]
[16] 余娅, 彭昌盛, 崔陶. 子宫平滑肌瘤的治疗药物研究进展[J]. 中国药物警戒, 2022, 19(6): 465-468.
[17] 王超, 安瑞芳, 何菊仙, 等. GnRH类似物对子宫肌瘤大鼠模型血液黏度、子宫系数和炎性细胞浸润的影响[J]. 现代生物医学进展, 2022, 22(4): 632-636.
[18] 杨家, 汤欣雨, 张漫, 等. 瑞卢戈利治疗子宫肌瘤的研究进展[J]. 实用药物与临床, 2023, 26(8): 764-768.
[19] Mustafa, A., Kumari, A.H., Haris, J., et al. (2021) Safety and Efficacy of Elagolix (with and without Add-Back Therapy) for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Leiomyomas: A Systematic Review and Meta-Analysis. Middle East Fertility Society Journal, 26, Article No. 20. [Google Scholar] [CrossRef] 
[20] Juliawati, M., Yusnita, Y., Imran, A., et al. (2022) Elagolix Treatment in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroid: A Systematic Review and Me-ta-Analysis. BMC Women’s Health, 22, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[21] 稂玲波, 李嘉宾. 促性腺激素释放激素拮抗剂研究进展[J]. 广东化工, 2021, 48(9): 138-140.
[22] 冀玉琼, 米清仙, 侯庆香. 醋酸乌利司他治疗子宫肌瘤临床研究[J]. 中国药业, 2022, 31(5): 106-108.
[23] Yousuf, S., et al. (2023) Efficacy and Safety of Repeated Use of Ulipristal Acetate in Uterine Fibroids. Mymensingh Medical Journal: MMJ, 32, 168-176.
[24] Kyeong, H.-K., et al. (2023) Effects of Long-Term Intermittent Pharmacological Therapy with Ulipristal Acetate on Reducing the Volume of Uterine Fibroids and Relieving Symptoms. Minerva Obstetrics and Gynecology, 75, 236-242. [Google Scholar] [CrossRef] 
[25] Natalia, P.N., Marla, C.V. and Raimundo, D.A. (2021) Ef-fects of Ulipristal Acetate in Patients with Symptomatic Uterine Fibroids. Medwave, 21, e8162. [Google Scholar] [CrossRef] [PubMed]
[26] Mohamed, G., Rana, M., Mohamed, S., et al. (2019) A Sys-tematic Review and Meta-Analysis of Ulipristal Acetate for Symptomatic Uterine Fibroids. International Journal of Gy-naecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics, 146, 141-148. [Google Scholar] [CrossRef] [PubMed]
[27] 吴敏. 不同剂量米非司酮治疗子宫肌瘤患者的临床疗效及对激素水平的影响[J]. 当代医学, 2022, 28(6): 125-127.
[28] 伊桂红, 王样莲. 米非司酮治疗女性子宫肌瘤的进展[J]. 北方药学, 2023, 20(8): 194-196.
[29] 欧定宏, 邓后亮, 李红梅. 米非司酮治疗子宫肌瘤的研究进展[J]. 中国药物经济学, 2019, 14(10): 120-124.
[30] 刘亚贤, 兰淑海. 米非司酮治疗子宫肌瘤药理学机制及临床应用研究进展[J]. 中国药物滥用防治杂志, 2022, 28(10): 1354-1357.
[31] 谈晓洁, 陆静, 邓海燕. 不同剂量米非司酮治疗子宫肌瘤的疗效与安全性评价[J]. 实用妇科内分泌电子杂志, 2023, 10(9): 78-80.
[32] 周朝荣. LNG-IUS治疗子宫肌瘤对患者宫肌瘤瘤体积血红蛋白水平的影响[J]. 基层医学论坛, 2021, 25(17): 2438-2439.
[33] 徐青, 付子毅, 马慧媛, 等. LNG-IUS治疗子宫肌瘤的临床效果及机制探讨[J]. 中国计划生育学杂志, 2018, 26(4): 274-278.
[34] 祁有花. 左炔诺孕酮宫内缓释系统应用在子宫肌瘤中的价值研究[J]. 医学食疗与健康, 2020, 18(16): 61+63.
[35] 张瑞, 聂敦利, 陈妍, 等. 来曲唑对子宫肌瘤细胞增殖凋亡及cAMP-PKA信号通路的影响[J]. 四川医学, 2020, 41(3): 267-271.
[36] 刘珏, 张潇迪, 张群锋. 来曲唑对子宫肌瘤细胞增殖凋亡的影响及其作用机制[J]. 实用医学杂志, 2019, 35(5): 688-691.
[37] 刘巧玲, 康小婕, 白云飞, 等. 子宫肌瘤的中医病因病机及中医药治疗进展[J]. 实用妇科内分泌电子杂志, 2022, 9(21): 45-48.
[38] 肖湉, 段小花. 药物治疗子宫肌瘤的研究概况[J]. 中国民族民间医药, 2022, 31(15): 50-55.
[39] 郝雨培, 崔妍彧, 赵若楠, 等. 中药治疗子宫肌瘤的作用机制研究进展[J]. 中国中医药图书情报杂志, 2021, 45(4): 69-73.
[40] 司玉红, 朱景华, 冀淑英, 等. 桂枝茯苓胶囊治子宫肌瘤临床研究[J]. 新中医, 2019, 51(10): 179-182.
[41] 吴海霞, 王瑛坚, 苑家林, 等. 桂枝茯苓丸治疗子宫肌瘤的临床疗效研究[J]. 长春中医药大学学报, 2021, 37(2): 362-364.
[42] 张雅宣, 余金明. 消癥丸治疗子宫肌瘤临床疗效的Meta分析[J]. 中国医药科学, 2022, 12(18): 35-38+86.
[43] 牛青凤, 费彩平. 消癥丸治疗气滞血瘀型子宫肌瘤的临床研究[J]. 基层医学论坛, 2016, 20(17): 2393-2394.
[44] 钟毅征, 黄嘉华, 潘美均, 等. 宫瘤清胶囊联合米非司酮治疗子宫肌瘤有效性的Meta分析[J]. 中国药房, 2020, 31(2): 221-226.
[45] 牛炜. 宫瘤清胶囊联合米非司酮治疗绝经前子宫肌瘤的临床研究[J]. 实用中西医结合临床, 2020, 20(5): 35-36+64.
[46] 屈颍卉, 席瑾. 宫瘤清胶囊联合西药治疗子宫肌瘤有效性和安全性Meta分析[J]. 新中医, 2019, 51(7): 32-37.
[47] Bi, C., Qiao, M., Jia, Y. and Wang, H. (2021) Network Meta-Analysis of 6 Kinds of Chinese Patent Medicines Combined with Mifepristone in the Treatment of Uterine Fibroids: A Protocol for Systematic Review and Network Meta-Analysis. Medicine (Baltimore), 100, e27523. [Google Scholar] [CrossRef] 
[48] 李珊珊, 李雪言, 王瑜. 宫瘤宁治疗子宫肌瘤疗效的研究进展[J]. 世界最新医学信息文摘, 2019, 19(61): 77-78.
[49] Shasha, S., Qiaobo, Y., Chenghao, Y., et al. (2021) The Efficacy and Safety of Xuefu Zhuyu Decoction Combined with Mifepristone in the Treatment of Uterine Leiomyoma: A Systematic Review and Meta-Analysis. Journal of Ethnopharmacology, 281, Article ID: 114551. [Google Scholar] [CrossRef] [PubMed]
[50] 温小娟, 陈柏君, 黄睿珏, 等. 血府逐瘀汤联合米非司酮治疗子宫肌瘤疗效和安全性Meta分析[J]. 中国药业, 2021, 30(13): 105-112.
[51] 陈绵, 陈燕娥, 吴学明. 丹鳖胶囊联合米非司酮对子宫肌瘤患者的临床疗效[J]. 中成药, 2020, 42(4): 1097-1099.
[52] 武亭宇, 王彬, 刘志强, 等. 丹鳖胶囊联合米非司酮治疗子宫肌瘤的有效性与安全性——基于Meta分析和试验序贯分析[J]. 河南大学学报(医学版), 2023, 42(1): 39-48+67.
[53] 韩兆忠, 刘茜, 郑伟然, 孟晓璞, 王振中, 萧伟. 桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤临床疗效和安全性的系统性评价[J]. 世界科学技术-中医药现代化, 2016, 18(3): 543-551.
[54] 章凯文, 谢鸣, 朱昊如. 桂枝茯苓丸联合米非司酮治疗子宫肌瘤随机对照试验的Meta分析[J]. 药物流行病学杂志, 2019, 28(11): 722-727.

为你推荐